Ferroptosis Emerges as a Targetable Vulnerability in Deadly Anaplastic Thyroid Cancer
A comprehensive review reveals how iron-driven cell death can be exploited to treat ATC, one of the most lethal human cancers.
Summary
Anaplastic thyroid cancer (ATC) kills most patients within a year and resists nearly all treatments. This review examines ferroptosis — a form of cell death triggered by iron-dependent lipid peroxidation — as a new therapeutic angle. ATC's genetic mutations (TP53, BRAF V600E, RAS, PIK3CA) and metabolic rewiring create dependence on antioxidant defenses, making cells vulnerable when those defenses are disrupted. Preclinical studies show that vitamin C, curcumin, neferine, shikonin, and drugs like anlotinib and dabrafenib can trigger ferroptosis in ATC models. Combination strategies — pairing BRAF inhibitors with GPX4 blockade, or natural compounds with chemotherapy — show additive tumor suppression. Nanoplatform delivery systems further enhance targeting. While systemic toxicity and resistance mechanisms remain challenges, ferroptosis-based strategies represent a mechanistically distinct and clinically promising new direction for this devastating cancer.
Detailed Summary
Anaplastic thyroid cancer (ATC) represents only 1–2% of thyroid cancers yet accounts for up to 50% of thyroid cancer-related deaths globally. Median overall survival remains under one year despite surgery, radiotherapy, chemotherapy, and even BRAF/MEK-targeted therapy. The near-universal resistance and relapse underscore the urgent need for entirely new therapeutic paradigms. This review by Lee and Roh synthesizes the current preclinical evidence for ferroptosis — a regulated, iron-dependent form of cell death — as an exploitable vulnerability in ATC, covering molecular mechanisms, pharmacological inducers, genetic regulators, and combination strategies.
Ferroptosis is mechanistically distinct from apoptosis and necroptosis. It is driven by the iron-catalyzed peroxidation of polyunsaturated fatty acids (PUFAs) within membrane phospholipids, producing lethal lipid hydroperoxides. Key executors include ACSL4 and LPCAT3, which incorporate arachidonic and adrenic acids into phosphatidylethanolamines. ATC cells show upregulated ACSL4 expression, enriching membranes with PUFA-containing phospholipids and predisposing them to peroxidation. Conversely, ACSL3-mediated monounsaturated fatty acid (MUFA) incorporation confers resistance by displacing PUFAs — a mechanism that may underlie adaptive resistance in some ATC tumors.
ATC's genomic landscape directly shapes ferroptosis sensitivity. TP53 mutations (>70% of ATCs) eliminate p53-mediated repression of SLC7A11, the cystine transporter that fuels glutathione (GSH) synthesis, paradoxically increasing antioxidant buffering. Yet certain TP53 mutations also elevate metabolic stress, potentially re-sensitizing cells under specific conditions. RAS mutations (~20%) elevate mitochondrial ROS and remodel lipid metabolism, increasing dependency on antioxidant defenses. BRAF V600E (~40%) drives adaptive metabolic resistance, but preclinical data show that combining BRAF inhibition with ferroptosis induction — specifically GPX4 blockade — can overcome this resistance. PIK3CA mutations promote NADPH production to buffer oxidative stress; inhibiting PI3K/AKT/mTOR reduces NADPH availability and weakens ferroptosis defenses.
Iron metabolism dysregulation is central to ATC's ferroptosis vulnerability. ATC cells overexpress transferrin receptor (TFRC/CD71), expanding the labile iron pool. Ferritinophagy — selective autophagic degradation of ferritin via NCOA4 — releases stored iron and sensitizes cells to ferroptosis. Vitamin C at pharmacological doses was shown to destabilize ferritin, increase free Fe2+, amplify Fenton chemistry, and trigger ferroptosis in ATC cells while suppressing long-term tumor growth in xenograft models. SIRT6 upregulation enhances NCOA4-mediated ferritin degradation and potentiates ferroptosis in ATC xenografts. HO-1, frequently overexpressed in ATC, plays a dual role: it can increase intracellular iron to promote ferroptosis or provide cytoprotection through antioxidant effects, depending on context.
Multiple pharmacological agents have demonstrated ferroptosis-inducing activity in ATC preclinical models. Anlotinib, a multikinase antiangiogenic inhibitor, suppresses ATC cell proliferation and metastasis by activating the autophagy–ferroptosis axis and downregulating GPX4, FTH1, and HO-1; co-administration of autophagy blockers further amplifies ferroptosis and enhances tumor regression. Natural compounds including neferine and curcumin suppress the Nrf2/HO-1 signaling pathway to induce ferroptosis. Shikonin and tenacissoside H also show ferroptosis-inducing effects in ATC models. Isobavachalcone combined with doxorubicin demonstrates additive ATC suppression. Novel Fe/curcumin-loaded ultrasound-responsive nanoplatforms achieve targeted 'domino-ferroptosis' in ATC xenografts, illustrating the translational potential of nanodelivery.
Despite this momentum, significant challenges remain. Resistance mechanisms include Nrf2 hyperactivation (which transcriptionally upregulates GPX4, SLC7A11, FTH1, and HO-1), MUFA remodeling, and compensatory activation of FSP1–CoQ10 and GCH1–BH4 axes. Predictive biomarkers — GPX4, SLC7A11, ACSL4, and FSP1 expression levels — need prospective clinical validation. Systemic toxicity from ferroptosis inducers, particularly in normal tissues with high iron turnover, must be managed. The review also highlights that RON receptor signaling links glycolysis to ferroptosis resistance, offering a novel therapeutic target. No clinical trials in ATC specifically targeting ferroptosis have yet been reported, making translation the critical next step.
Key Findings
- ATC harbors TP53 mutations in >70% of cases and TERT promoter mutations in >70%, both of which influence redox balance and ferroptosis sensitivity
- BRAF V600E (~40% of ATCs) drives adaptive metabolic resistance, but preclinical studies show combining BRAF inhibition with GPX4 blockade can overcome this resistance
- Vitamin C at pharmacological doses induces ferritinophagy, increases labile Fe2+, and triggers ferroptosis in ATC cells, suppressing long-term tumor growth in xenograft models
- Anlotinib suppresses ATC proliferation and metastasis via the autophagy–ferroptosis axis by downregulating GPX4, FTH1, and HO-1; autophagy blockade further amplifies ferroptotic tumor regression
- ACSL4 upregulation in ATC enriches membranes with PUFA-containing phospholipids, predisposing cells to lipid peroxidation and ferroptosis
- SIRT6 upregulation enhances NCOA4-mediated ferritinophagy and potentiates ferroptosis in ATC xenograft models
- Fe/curcumin-loaded ultrasound-responsive nanoplatforms achieve targeted 'domino-ferroptosis' in ATC xenografts, demonstrating nanodelivery as a viable translational strategy
Methodology
This is a comprehensive narrative review article, not a primary clinical trial or meta-analysis. The authors systematically synthesized published preclinical studies, genomic sequencing data, and mechanistic investigations from cell line and xenograft models of ATC. No original patient cohorts or statistical analyses were performed by the authors; effect sizes and p-values cited are drawn from the referenced primary studies. The review covers in vitro cell viability assays, xenograft tumor regression experiments, genetic knockdown/overexpression studies, and pharmacological intervention models across multiple ATC cell lines.
Study Limitations
As a review article, all evidence is derived from preclinical cell line and xenograft studies; no clinical trial data in ATC patients specifically targeting ferroptosis currently exist, limiting direct translational conclusions. The dual roles of key regulators such as HO-1 and Nrf2 — which can either promote or inhibit ferroptosis depending on context — introduce complexity that has not been fully resolved in ATC-specific models. The authors declare no conflicts of interest, and the study was funded by the National Research Foundation of Korea.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.